Incidence of Clostridium difficile infection and enteric pathogens in children with inflammatory bowel disease presenting with disease exacerbation - Takeaways - MDSpire

Incidence of Clostridium difficile infection and enteric pathogens in children with inflammatory bowel disease presenting with disease exacerbation

  • By

  • Kaltham Al-Shaibah

  • Reham Jasem

  • Ali Alsarhan

  • Christos Tzivinikos

  • May 13, 2026

  • 0 min

Share

  • 1

    The study assessed the prevalence of Clostridioides difficile infection (CDI) and other enteric pathogens in children with inflammatory bowel disease (IBD) during exacerbations.

  • 2

    Out of 144 stool analyses, 32.6% tested positive for infectious agents, with CDI and E. coli being the most frequently detected pathogens.

  • 3

    Children with Crohn's disease had a higher incidence of CDI (17.2%) compared to those with ulcerative colitis (8.5%).

  • 4

    Patients receiving biological treatments faced a significantly higher risk of CDI compared to those not on biological therapy (17.9% vs. 6.9%).

  • 5

    The findings highlight the importance of systematic pathogen evaluation in pediatric IBD patients exhibiting exacerbating symptoms.

Original Source(s)

Incidence of Clostridium difficile infection and enteric pathogens in children with inflammatory bowel disease presenting with disease exacerbation

  • by Kaltham Al-Shaibah, Reham Jasem, Ali Alsarhan, Christos Tzivinikos

  • May 13, 2026

Related Content

Macrophage dysregulation in inflammatory bowel disease: cellular heterogeneity, pathogenic mechanism, and treatment

Colorectal Cancer Treatment During Pregnancy

Colorectal cancer (CRC) impacts about 1 in 13,000 pregnancies in the United States. This article follows the case of a 36-year-old woman diagnosed with CRC while pregnant and highlights considerations around CRC diagnosis and cancer treatment during pregnancy.

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min